Introduction
Blast cells in the majority of patients with acute leukemia can be unequivocally assigned to a specific lineage, whether myeloid, B-or T-lymphoid. However, in about 2-5% of patients lineage origin remains ambiguous even after comprehensive immunophenotyping by flow cytometry (FCM). Historically, a variety of terms have been used to describe such cases, such as mixed lineage leukemia, hybrid acute leukemia, bilineal leukemia, and biphenotypic leukemia. [1] [2] [3] [4] [5] The 2008 WHO classification of hematopoietic and lymphoid tumors (WHO-2008) modified the diagnostic criteria and introduced a new designation for this entity, now termed mixed-phenotype acute leukemia (MPAL). 6 The clinical and laboratory features of mixed lineage leukemia, hybrid acute leukemia, bilineal leukemia, or biphenotypic leukemia have been described in a few retrospective studies. [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] However, given the dearth of reports hitherto, the features about the clinical and laboratory features of patients with MPAL remain largely undefined. In the sole investigation reported to date, patients with MPAL were reassessed, comprising 2 infants, 28 children, and 68 adults, as defined per WHO-2008. 14 Here, we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular genetic features of patients with MPAL as defined under WHO-2008 criteria.
Design and methods

Patients
The study was approved by the 
Immunophenotyping
FCM immunophenotyping was performed on blast populations using FACSCalibur instruments (BD Biosciences, San Jose, CA). All cases were characterized with a panel of antibodies to leukocyte-associated markers, including surface CD2, CD3 (and cytooplasmic cyCD3), CD5, CD7, CD10, CD11b, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, (cyCD22), CD33, CD34, CD45, CD64, CDw65, CD79a, (cyCD79a), CD117, HLA-DR, TdT, and myeloperoxidase (MPO).
Surface antigen expression was considered positive when more than 20% of blasts showed a positive signal. For cytoplasmic antigens, the threshold was set at 10%. Data visualization was performed with Agilent Genomic Workbench Lite Edition 6.5
Cytogenetic and molecular genetic analysis
software.
Statistical analysis
Patient characteristics were analyzed by chi-squared ( 2) or Fisher exact tests for univariate analysis. P-values less than 0.05 were deemed significant. All calculations were performed using the SPSS software package (version 13.0).
Results and Discussion
Patients
Among 4780 patients admitted to our institute since 1998, we identified 117 adult immunophenotyping data are summarized in Table 1 .
Our immunophenotyping data revealed significant gender differences in MPAL subtypes, with male excesses in B+T and T+My groups, but female predominance in B+My patients, thus contrasting with the data of Matutes et al. 14 Further studies are needed to clarify the issue, and in particular whether ethnic or genetic factors might contribute to these discrepancies in gender distribution of MPAL cases.
It is presumed that MPAL arises from multipotent stem cells, capable of differentiating into myeloid and lymphoid progenitors during the development of acute leukemia. In this study, a marker of early hematopoietic cells, CD34, was strongly positive in 82% cases, reinforcing the notion that MPAL cells originate at early stages of hematopoietic differentiation.
Cytogenetics
Of the 92 patients with available karyotypic data, 33 (36%) had no detectable chromosomal abnormality, while the remaining 59 (64%) showed abnormal karyotypes. Complex karyotypic abnormalities (≥3 aberrations) described the most prolific subclass, found in 22 cases (24%). The t(9;22)(q34;q11)/BCR-ABL1 fusion were present in 14 patients (15%) -all with B+My phenotypes. Monosomy 7 was detected in 7/92 cases (7.6%). Polysomy 21 was unexpectedly found in 7/92 (7.6%)
cases. Trisomy 8 occurred in 5 (5.4%) cases -all with B+My phenotypes.
t(v;11q23)/MLL rearrangements were seen in 4 (4.3%) patients, of which 2 had t(11;19)(q23;p13), while one patient each carried t(4;11)(q21;q23) and t(9;11)(p22;q23), respectively. t(10;11)(p15;q21) was present in 3 (3.3%) cases, including two with T+My and one with B+T phenotypes. In three cases, translocations not previously reported in leukemia were found: t(7;9)(q32;p24) with B+My phenotype, t(2;9)(q13;q34) with B+T phenotype, and der(9)t(9;11)(p21;q12) with T+My phenotype.
A novel fusion between NUP98 and IQCG gene was identified in a MPAL patient with
T+My phenotype harboring t(3;11)(q29q13;p15)del(3)(q29) as previously described. Table 1 .
Of patients provided with cytogenetic data, 64% showed abnormal karyotypes.
Like in previous reports, the cytogenetic groups most commonly described in MPAL or biphenotypic leukemia, namely, those with complex karyotypes, t(9;22)(q34;q11) and t(v;11q23), were also detected by us in a substantial proportion of MPAL cases, present in 24%, 15%, and 4.3% of patients respectively.
Importantly, we identified four recurrent cytogenetic changes for the first time in a significant number of MPAL patients: monosomy 7 in 7.6%, polysomy 21 in 7.6%, t(10;11)(p15;q21) in 3.3%, and 1p32 deletion effecting STIL-TAL fusion in 1.1%.
Monosomy 7 is one of the most frequent chromosome abnormalities detected in patients with myelodysplastic syndromes and AML, where it is associated with a relatively poor prognosis. 17 It may also be found in patients with CML-BC or Ph+ ALL.
Acquired isolated trisomy 21 is a frequent cytogenetic abnormality in myeloid malignancies, and has been reported as an anomaly accompanying t(12;21)(p13;q22)
in childhood B-cell ALL. Several studies in leukemia patients with trisomy 21 showed frequent mutations of RUNX1 -often duplicated as a consequence of the trisomy. 18 However, mutations of RUNX1 were absent in all 4 MPAL patients screened for RUNX1 mutation in this study. t(10;11)(p15;q21), resulting in PICALM-MLLT10 fusion, is a recurrent chromosomal translocation seen in AML or ALL patients showing T+My or B+T phenotype. STIL-TAL1 fusion results from 1p32 microdeletion and is detected in 10-25% of T-ALL. This is the first report indicting these four cytogenetic alterations in the pathogenesis of MPAL.
Frequencies and distribution of gene mutations
In the past decade, with the advent of the novel genomic microarray technologies, In the present study, we evaluated a variety of acute leukemia-related mutations.
After excluding known polymorphisms and silent mutations, a total of 12 mutations (39%) were documented ( 
Array-based comparative genomic hybridization analysis of 12 MPAL samples
Genomic microarrays provide powerful tools enabling global high-resolution analysis of submicroscopic chromosome deletions, amplifications, and unbalanced chromosome rearrangements. They are widely used in the molecular genetic studies of hematologic malignancies and have helped identify many important cryptic leukemia-related genetic alterations, such as IKZF1 deletion, MYB duplication, LEF1
deletion, SET-NUP214 fusion, PAX5 deletion, and TET2 mutation. This is the first molecular genomic study of MPAL or biphenotypic leukemia. We performed array-CGH analysis on 12 MPAL samples and found that all had one or more genomic abnormalities ( 24 All of these cryptic gene lesions listed above are described here for the first time in MPAL patients.
Treatment and clinical response of MPAL patients
Currently, the optimal therapy for patients with MPAL is still unclear. There is little consensus whether induction therapy should follow AML and/or ALL chemotherapy and whether HSCT might be effective. We compared the relative efficacies of the combination of AML+ALL therapy and of the CAG regimen in induction therapy on 34 MPAL patients at presentation. MOAP/IOAP/DOAP was administered to 24 MPAL patients, of whom 14 (58%) achieved complete remission (CR), while two died from severe infection. The remaining 10 patients received induction therapy according to the CAG regimen of whom 7 (70%) achieved CR. The difference in CR rates between the two groups was not significant (P=0.802). However, interestingly, 5 of the 6 patients (83%) who failed to respond to MOAP/IOAP/DOAP therapy attained CR after receiving the CAG regimen. Furthermore, the overall survival rate of patients with MPAL in 8 patients receiving allo-HSCT was longer than the 13 receiving consolidation chemotherapy (22.0 versus 9.0 months; P=0.004). Thus, it seems patients receiving allo-HSCT had the better outcomes. However, owing to the limited numbers of patients who received allo-HSCT in this study, further studies with more cases are needed to determine its role in MPAL therapy.
In summary, this study demonstrates that adult MPAL is a complex entity with heterogeneous clinical, immunophenotypic, and genetic characteristics. We observed widespread differences in the cytogenetic and molecular features of adult MPAL versus AML or ALL. We also identified gene mutations or cryptic copy number 
